Global Chemotherapy Induced Nausea and Vomiting Drugs Market, By Type (Acute Emesis, Delayed Emesis, Anticipatory Emesis and Refractory Emesis), Therapy (Nk-1 Receptor Antagonist, Serotonin Receptor Antagonist and Others), Population Type (Children’s and Adults), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Chemotherapy Induced Nausea and Vomiting Drugs Market Analysis and Size
Rising number of patients undergoing chemotherapy and increasing compliance to chemotherapy drugs and highly potential newer drugs will give boost to the market growth. The expansion of company’s and increase in product portfolio market along with the new advancement in delivery type will add numerous opportunities that will commence to the germination of the global chemotherapy induced nausea and vomiting drugs market in the above-mentioned forecast period of 2023 to 2030.
Data Bridge Market Research analyses that the global chemotherapy induced nausea and vomiting drugs market which was USD 1,995.87 million in 2022, is expected to reach USD 4,672.82 million by 2030, and is expected to undergo a CAGR of 6.6% during the forecast period of 2023 to 2030. “Acute Emesis” dominates the product segment of the global chemotherapy induced nausea and vomiting drugs market owing to advancement in chemotherapy. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chemotherapy Induced Nausea and Vomiting Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute Emesis, Delayed Emesis, Anticipatory Emesis and Refractory Emesis), Therapy (Nk-1 Receptor Antagonist, Serotonin Receptor Antagonist and Others), Population Type (Children’s and Adults), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of the Middle East and Africa
|
|
Market Players Covered
|
Eisai (Japan), ProStrakan (U.K.), Helsinn Holding (Switzerland), Mundipharma (Singapore), Qilu Pharma (China), Novartis AG (Switzerland), Heron Therapeutics (U.S.), Roche (Switzerland), Tesaro (U.S.), Helsinn Holding S.A. (Switzerland), Baxter (U.S.), Orchid Healthcare (India), Sun Pharmaceutical Industries Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Chemotherapy induced nausea and vomiting is one of the most common and distressing acute side effects of cancer treatment. It occurs in up to 80% of patients and can have a significant impact on a patient's quality of life. Nausea and vomiting can also result serious metabolic derangements nutritional depletion and anorexia.
Global Chemotherapy Induced Nausea and Vomiting Drugs Market Dynamics
Drivers
- Increasing Cancer Incidence
The increasing global cancer incidence is a significant driver for the global chemotherapy induced nausea and vomiting drugs market. As more patients undergo chemotherapy, the demand for effective CINV management and prevention rises. As the number of cancer cases grows, more patients require CINV drugs to alleviate side effects.
- Advancements in Chemotherapy
The development of newer and more potent chemotherapy drugs can lead to more severe side effects, including CINV. This drives the need for improved CINV drugs to enhance patient comfort and compliance with treatment. For instance, highly melogenic chemotherapy regimens may necessitate more robust CINV drug interventions.
- Expanding Geriatric Population
The aging global population is more prone to cancer and its associated treatments. This demographic shift increases the number of patients requiring CINV management. For instance, older patients may be more susceptible to CINV, necessitating tailored drug therapies.
Opportunities
- Development of Targeted Therapies
Continued research and development can lead to more targeted and effective CINV drugs with fewer side effects. For instance, the development of novel 5-HT3 receptor antagonists or NK1 receptor antagonists with improved efficacy and tolerability.
- Personalized Medicine and Profile
Tailoring CINV management to individual patient profiles can lead to better outcomes and is an emerging opportunity in the market. For instance, identifying patients at high risk of CINV through genetic testing and customizing drug regimens.
Restraints/Challenges
- Side Effects of CINV Drugs
Some CINV drugs themselves can have side effects, which may affect patient compliance and limit their use. For example, common side effects of antiemetic CINV drugs include dizziness and fatigue, which can be challenging for patients.
- Cost of Treatment
The cost of CINV drugs and their combination with chemotherapy can add to the overall treatment expense, potentially limiting access for some patients. For instance, the high cost of certain CINV drugs may pose challenges to affordability.
- Variability in Patient Response
Different patients may respond differently to CINV drugs, making it challenging to find a universally effective treatment. For example, individual patient characteristics and genetics can influence drug efficacy.
This global chemotherapy induced nausea and vomiting drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chemotherapy induced nausea and vomiting drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chemotherapy Induced Nausea and Vomiting Drugs Market Scope
The global chemotherapy induced nausea and vomiting drugs market is segmented on the basis of type, therapy, population type, drug type, and route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Type
- Acute emesis
- Delayed emesis
- Anticipatory emesis
- Refractory emesis
Therapy
- Nk-1 receptor antagonist
- Serotonin receptor antagonist
- Others
Population Type
- Children
- Adults.
Drug Type
- Branded
- Generic
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Chemotherapy Induced Nausea and Vomiting Drugs Market Regional Analysis/Insights
The global chemotherapy induced nausea and vomiting drugs market is analysed and market size insights and trends are provided by type, therapy, population type, drug type, route of administration, end user and distribution channel as referenced above.
The countries covered in the global chemotherapy induced nausea and vomiting drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America governs the global chemotherapy induced nausea and vomiting drugs market owing to the according to the annual report by American Cancer Society approximately 1.6 million population would be effected by cancer in U.S..
Asia-Pacific is expected to show a rapid and lucrative growth rate in the global chemotherapy induced nausea and vomiting drugs market during forecast period of 2023 to 2030 due to significant rise in cancer patients and increase in the use of chemotherapy drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global chemotherapy induced nausea and vomiting drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global chemotherapy induced nausea and vomiting drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global chemotherapy induced nausea and vomiting drugs market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Chemotherapy Induced Nausea and Vomiting Drugs Market Share Analysis
The global chemotherapy induced nausea and vomiting drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chemotherapy induced nausea and vomiting drugs market.
Some of the major players operating in the global chemotherapy induced nausea and vomiting drugs market are:
- Eisai (Japan)
- ProStrakan (U.K.)
- Helsinn Holding (Switzerland)
- Mundipharma (Singapore)
- Qilu Pharma (China)
- Novartis AG (Switzerland)
- Heron Therapeutics (U.S.)
- Roche (Switzerland)
- Tesaro (U.S.)
- Helsinn Holding S.A. (Switzerland)
- Baxter (U.S.)
- Orchid Healthcare (India)
- Sun Pharmaceutical Industries Ltd. (India)
SKU-